EGFR and non-small cell lung carcinoma: Small-molecule tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib, could specifically inhibit epidermal growth factor receptor (EGFR)-dependent pathway activity, could prolong OS and/or progression-free survival (PFS) in patients with advanced NSCLC and harboring an EGFR mutation [8, 9].